Loading stock data…
$90.17+1.16 (+1.30%)
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
BioNTech SE in the Healthcare sector is trading at $90.17 with a market capitalization of $24.2B. Wall Street consensus targets $115.69 (20 analysts), implying a +28.3% move over the next 12 months. The stock is currently 27% below its 52-week high of $124.00, remaining 7.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.60M↓ | $118.10M↓ | $907.40M↓ | $1.52B↑ | $260.80M |
| Gross Profit | $8.60M↓ | $46.70M↓ | $574.10M↓ | $1.37B↑ | $184.40M |
| Operating Income | -$938.70M↓ | -$671.20M↓ | -$280.50M↓ | $653.90M↑ | -$472.00M |
| Net Income | -$820.80M↓ | -$531.90M↓ | -$305.00M↓ | -$28.70M↑ | -$386.60M |
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...